Clinical Trials in Thalassemia Cell and Gene Therapy Application supports investigators conducting cell and gene therapy trials and related preclinical work to advance a cure for thalassemia.
Applications for 2027–2028 are now open; the December 15, 2025 LOI and February 9, 2026 application deadlines were removed without replacements. Indirect costs increased from 8% to up to 10%, in vivo gene therapy and toxicity-reduction proposals are now encouraged, and other application details also changed.
Funder: Thalassemia Foundation of America (formerly Cooley’s Anemia Foundation)
Due Dates: February 1, 2027 (Renewal application)
Funding Amounts: Up to $75,000 per year; second-year renewal possible (renewal form caps requests at $60,000)
Summary: Supports cell and gene therapy clinical trials and related preclinical work to advance a cure for thalassemia.
Key Information: National and international applicants are eligible; research cannot be conducted at a for-profit laboratory.
The Thalassemia Foundation of America supports national and international investigators advancing cell and gene therapies toward a cure for thalassemia. The program funds phase I safety trials and phase II efficacy trials, with particular encouragement for in vivo gene therapy approaches and strategies to reduce gene therapy toxicity.
Support may address any aspect of launching a human gene therapy trial, including clinical-grade vector production, quality control, research subject assessments, and study-related patient care. Late-preclinical and ex vivo studies needed to assess safety and efficacy are also eligible, including studies of vector genome integration, transduction efficiency, and globin production by transduced hematopoietic stem cells. Proposals must provide a realistic timeline toward human trials; the Foundation recognizes that this timeline may be long.